candesartan cilexetil has been researched along with Atherogenesis in 1 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chow, BS | 1 |
| Koulis, C | 1 |
| Krishnaswamy, P | 1 |
| Steckelings, UM | 1 |
| Unger, T | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Allen, TJ | 1 |
1 other study available for candesartan cilexetil and Atherogenesis
| Article | Year |
|---|---|
The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles | 2016 |